Iran Allows 'Non-Hostile' Vessels to Transit Strait of Hormuz

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 1 day ago

0mins

ACHV-28.4%

Should l Buy ACHV?

Source: seekingalpha

Transit Policy: Iran informed the International Maritime Organization that 'non-hostile' vessels may pass through the Strait of Hormuz if they coordinate with Iranian authorities, aiming to alleviate the shipping crisis caused by ongoing conflicts.
Shipping Disruption Impact: Since the conflict erupted on February 28, shipping through the Strait has nearly ceased, leaving approximately 3,200 vessels stranded in the Gulf, affecting 20% of global oil shipments and trade for Gulf nations.
Transit Costs: Some shipping operators have reportedly paid up to $2 million to secure safe passage, reflecting the significant impact of the current situation on shipping costs and operational risks.
Humanitarian Corridor Exploration: The International Maritime Organization is considering establishing a humanitarian corridor to allow vessels facing fuel or supply shortages to safely exit the region, highlighting the importance of maritime safety amidst escalating tensions.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ACHV?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ACHV

Wall Street analysts forecast ACHV stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.900

Low

12.00

Averages

15.50

High

19.00

Current: 2.900

Low

12.00

Averages

15.50

High

19.00

H.C. Wainwright

maintain

$12

2026-02-06

Reason

H.C. Wainwright

Price Target

$12

AI Analysis

2026-02-06

maintain

Reason

H.C. Wainwright views Pfizer's (PFE) launch of Chantix among the 30 medicines it placed on the White House's direct-to-consumer site, TrumpRx, as "a significant positive" for Achieve Life Sciences (ACHV) and cytisinicline, arguing that the news removes the potential of Pfizer bringing Chantix back to market and putting any marketing dollars behind the product. The move to include Chantix on TrumpRx is "not random or economically driven," but rather likely a concession to the Make America Healthy Movement within the current administration, which bodes well for the potential for cytisinicline's chances of approval by the current PDUFA date on June 20, adds the analyst, who has a Buy rating and $12 price target on Achieve shares.

JMP

Jason Butler

Outperform

initiated

$19

2025-11-25

Reason

JMP

Jason Butler

Price Target

$19

2025-11-25

initiated

Outperform

Reason

Citizens JMP analyst Jason Butler initiated coverage of Achieve Life Sciences with an Outperform rating and $19 price target. Achieve is developing cytisinicline, a nicotine dependence treatment for smoking cessation in adults, the analyst tells investors in a research note. The firm believes cytisinicline has a "highly differentiated" profile to Chantix and can both supplant and grow the current market.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACHV

Unlock Now

About ACHV

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ACHIEVE LIFE SCIENCES INC REPORTS Q4 NET LOSS OF $14.7 MILLION, FY2025 NET LOSS TOTALS $54.7 MILLION

1 day agomoomoo

Q4 Financial Performance: The company reported a net loss of $14.7 million for the fourth quarter.
FY 2025 Projections: For the fiscal year 2025, the projected net loss is $54.7 million.

Major Earnings Reports Expected Before Tuesday's Open: Xiaomi and More

2 days agoseekingalpha

Earnings Release Preview: Major companies including Xiaomi Corporation (XIACF) are set to report earnings before the market opens on Tuesday, which is expected to influence market sentiment, particularly amid mixed performance in tech stocks.
Diverse Company Participation: In addition to Xiaomi, Vertical Aerospace Ltd. (EVTL), Concentrix Corporation (CNXC), Achieve Life Sciences (ACHV), and Hesai Group (HSAI) will also release earnings on the same day, highlighting market interest in a variety of sectors.
Market Reaction Expectations: Investors will closely monitor these earnings reports to assess the potential impact on stock prices, especially in the current economic climate where changes in corporate profitability could trigger market volatility.
Comprehensive Earnings Calendar: Seeking Alpha provides a full earnings season calendar, allowing investors to access more information to better seize investment opportunities.

Achieve Life Sciences Q4 2025 Earnings Call Insights

1 day agoseekingalpha

Clinical Transition Progress: Achieve Life Sciences submitted the NDA for cytisinicline in June 2025, marking a shift from clinical to commercial focus, aiming to provide treatment for 25 million smokers and nearly 18 million vapers, demonstrating the company's keen awareness of market demand.
Regulatory Milestone Achieved: The FDA accepted the NDA for cytisinicline and granted a National Priority Voucher for the vaping indication, providing an accelerated pathway to potential first-in-class approval for vaping cessation, which holds significant market potential.
Financial Status Update: As of December 31, 2025, the company reported $36.4 million in cash and cash equivalents, with operating expenses of $14.7 million and a net loss of $14.7 million, reflecting ongoing investments in regulatory and commercial preparations despite a cash decrease from the previous quarter.
Market Readiness and Risk Management: Management has engaged with payers approximately 40 times, emphasizing the differentiated profile of cytisinicline and the unmet market needs, while planning to initiate the ORCA-V2 Phase III trial in vaping cessation in the first half of 2026, showcasing the company's strategic focus on market access and supply chain security.